Virios Therapeutics Announces Data Demonstrating Improvement In Multiple Long-Covid Symptoms Following Treatment With Valacyclovir/Celecoxib Combo In An Exploratory, Open-label, Proof Of Concept Study
Portfolio Pulse from Benzinga Newsdesk
Virios Therapeutics has announced data showing improvement in multiple long-Covid symptoms following treatment with a combination of Valacyclovir and Celecoxib. The data comes from an exploratory, open-label, proof of concept study.
July 17, 2023 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Virios Therapeutics' stock may see positive movement following the announcement of promising data from a study on a treatment for long-Covid symptoms.
The announcement of positive data from a study on a treatment for long-Covid symptoms is directly related to Virios Therapeutics' core business. This news could increase investor confidence in the company and potentially lead to a rise in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100